TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04872335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's Mobilization
Description: Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gradually Graded Exercise Therapy
Description: The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug.
Study: NCT02685488

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Ultrasound Power
Description: Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound Sham
Description: Transcranial ultrasound will be used without power for a sham condition.
Study: NCT00866866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: 600 mg PO BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab PO BID
Study: NCT02980718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive olfactory training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ordinary olfactory training
Study: NCT04576858

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA
Description: Measurement of circulating tumor DNA from plasma over a period of 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA
Description: Measurement of circulating tumor DNA from plasma over a period of 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA
Description: Measurement of circulating tumor DNA from plasma over a period of 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA
Description: Measurement of circulating tumor DNA from plasma over a period of 2 years.
Study: NCT02523651

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DPSC injection
Description: A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
Study: NCT04905225

Intervention type: PROCEDURE
Intervention: Ascending aortic replacement
Description: Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
Study: NCT00586586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
Study: NCT04575285

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram (EEG)
Description: EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
Study: NCT04710225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting
Description: Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting
Description: Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure.
Study: NCT02975037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil 25 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil 25 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: clarithromycin 250 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: itraconazole 100 mg PO
Study: NCT01570816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS-8 (8 channel implanted receiver stimulator)
Description: Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
Study: NCT02269644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: dalbavancin 1500 mg IV over 30 minutes on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Linezolid Placebo
Description: Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
Study: NCT02165306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Description: All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
Study: NCT04250831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: agglomerated glucomannan, oligofructose and chromium mixture
Description: Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
Study: NCT00845325

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group One
Description: They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group Two
Description: The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
Study: NCT03282006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pivmecillinam
Description: Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
Study: NCT02976259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
Study: NCT02610764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test for CTC evaluation
Study: NCT04109313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
Study: NCT03188094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW-Led Health Coaching
Description: The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Alerts
Description: Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI \>23 kg/m2 and registries to track outcomes.
Study: NCT01924780

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEMOS Device sham stimulation 10 minutes
Study: NCT01416025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospective TDM Arm
Description: Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Study: NCT02236676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nap after rehearsal trials
Description: Behavioral

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nap after rehearsal trials
Description: Behavioral
Study: NCT02950337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 1: Peripherally Located Tumors
Description: Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 2: Peripherally Located Chest Wall Adjacent Tumors
Description: Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group 3: Centrally Located Tumors
Description: Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
Study: NCT03755193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of SERM and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of SERM and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of SERM and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonates and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of BP and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonates and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of BP and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonates and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of BP and ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELD Edirol®Tablet 0.75ug
Description: To examine the effects of ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELD Edirol®Tablet 0.75ug
Description: To examine the effects of ELD in osteoporosis patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELD Edirol®Tablet 0.75ug
Description: To examine the effects of ELD in osteoporosis patients
Study: NCT03563547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling (fat modifed diet)
Description: Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
Study: NCT03851237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-ECLIi
Description: -The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-ECLIi
Description: -The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
Study: NCT03563547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling (fat modified + soy enriched diet)
Description: Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target.
Study: NCT02045602

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: 125 mg/m2 intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: 125 mg/m2 intravenous administration
Study: NCT03851237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-ECLIi
Description: -The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
Study: NCT01493414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Study: NCT02675829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
Study: NCT03037970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhPDGF-BB
Description: One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen Wound Dressing wetted with buffer.
Study: NCT04439266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study: NCT03851237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -Standard of care
Study: NCT01648543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar sympathetic ganglion block
Study: NCT03851237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -Standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -Standard of care
Study: NCT01463046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Study: NCT03895372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 or Placebo
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 or Placebo
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 or Placebo
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 or Placebo
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period